Skip to content

Clinical study of postoperative radiotherapy to prevent recurrence on hepatocellular carcinoma patients with microvascular invasion undergoing hepatectomy

Clinical study of postoperative radiotherapy to prevent recurrence on hepatocellular carcinoma patients with microvascular invasion undergoing hepatectomy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017371
Enrollment
Unknown
Registered
2018-07-26
Start date
2015-10-01
Completion date
Unknown
Last updated
2018-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary hepatocellular carcinoma

Interventions

control:regular follow-up
intervention group:postoperative radiotherapy

Sponsors

Cancer Hospital, Chinese Academy of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. primary hepatocellular carcinoma; 2. less than 70 years, without severe complications of circular, respiratory or metabolic system; 3. Child-pugh A grade, ICG-R15<15%; 4. single lesion without extrahepatic metastasis or portal vein tumor thrombus proven by preoperative imaging examination; 5. R0 resection proven by postoperative pathology; 6. surgical margin less than 2 centimeter; 7. micro vascular invasion proven by postoperative pathology; 8. receive postoperative regular antiviral treatment.

Exclusion criteria

Exclusion criteria: 1. cannot sign consent form independently due to cognitive disorder; 2. synchronous/metachronous extrahepatic organ or system malignant; 3. major extrahepatic organ resection were performed synchronously; 4. with contraindication of radiotherapy; 5. with severe postoperative intra-abdominal infection; 6. with postoperative intestinal or biliary fistula; 7. with postoperative severe hepatic insufficiency; 8. other conditions that patients were not suitable for the study.

Design outcomes

Primary

MeasureTime frame
relapse free survival;

Secondary

MeasureTime frame
overall survival;pattern of recurrence;

Countries

China

Contacts

Public ContactWang Liming

Cancer Hospital, Chinese Academy of Medical Science

stewen_wang@sina.com+86 18911597091

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 26, 2026